Oncology

Back to articles

Exemestane reduces breast cancer risk in postmenopausal women

KEY POINT

In a large clinical trial of postmenopausal women with a moderately increased risk for breast cancer, the aromatase inhibitor exemestane reduced the number of invasive breast cancers.

SOURCES

Goss PE et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364:2381–91.

Davidson NE, Kensler TW. “MAPping” the course of chemoprevention in breast cancer [editorial]. N Engl J Med. 2011;364:2463–4.